Study of MSC303 for immune-related kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called MSC303 for people with certain immune-related kidney diseases, like lupus nephritis or ANCA-associated glomerulonephritis. It aims to see if the drug is safe and helps the kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have either lupus nephritis or ANCA-associated glomerulonephritis.
- Your kidneys are working well enough for the study.
- You must not have a history of severe allergic reactions to similar drugs or any ingredient in MSC303.
- You must not have an active infection needing antibiotics or other serious illnesses.
- You must not have HIV, hepatitis B, or hepatitis C.
- You are willing to follow the study rules and give your consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
This study tests a new injection called MTM-H-001 to treat autoimmune diseases where the body's B cells attack itself (like rheumatoid arthritis or lupus). The trial aims to see if this treatment is safe and effective for adults.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
This trial tests a new drug called SIM0278 for people with active lupus nephritis (kidney inflammation caused by lupus). It aims to see if adding this drug to standard treatment is safe and helpful for controlling the disease.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.